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Methylene blue has been shown to be neuroprotective in multiple experimental
neurodegenerative disease models. However, the mechanisms underlying the
neuroprotective effects have not been fully elucidated. Previous studies have shown that
macroautophagy has multiple beneﬁcial roles for maintaining normal cellular homeostasis
and that induction of macroautophagy after myocardial ischemia is protective. In the
present study we demonstrated that methylene blue could protect HT22 hippocampal cell
death induced by serum deprivation, companied by induction of macroautophagy.We also
found that methylene blue-mediated neuroprotection was abolished by macroautophagy
inhibition. Interestingly, 5′ adenosine monophosphate-activated protein kinase (AMPK)
signaling, but not inhibition of mammalian target of rapamycin signaling, was activated
at 12 and 24 h after methylene blue treatment in a dose-dependent manner. Methylene
blue-induced macroautophagy was blocked by AMPK inhibitor. Consistent with in vitro
data, macroautophagywas induced in the cortex and hippocampus ofmouse brains treated
with methylene blue. Our ﬁndings suggest that methylene blue-induced neuroprotection
is mediated, at least in part, by macroautophagy though activation of AMPK signaling.
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INTRODUCTION
Methylene blue has long been used as treatment for methe-
moglobinemia (Dotsch et al., 2000; Zenk, 2001; Matisoff and
Panni, 2006), ifosfamide neurotoxicity (Raj et al., 2004; Patel,
2006; Richards et al., 2011), malaria (Rengelshausen et al., 2004;
Zoungrana et al., 2008; Coulibaly et al., 2009; Krafts et al., 2012).
Recent studies suggest that methylene blue plays a critical
role in neuroprotection against ischemic stroke and Parkin-
son’s disease due to its capability as an alternative mitochondria
electron carrier (Wen et al., 2011). A very recent study indi-
cates that methylene blue reduced Tau protein aggregates in
Alzheimer’s disease through inducing macroautophagy (Congdon
et al., 2012).
Macroautophagy is one of the main mechanisms for maintain-
ing cellular homeostasis, including for maintaining homeostasis
and functions of central nervous system (Komatsu et al., 2006;
Xilouri and Stefanis, 2010; Marino et al., 2011). In the soma,
macroautophagy occurs to maintain normal cellular homeosta-
sis. In the axons, axotomy and excitotoxic insult trigger the
accumulation of autophagosomes in dystrophic axonal swellings
(Yue et al., 2008, 2009). In addition, studies also show that
macroautophagy plays a signiﬁcant role against the progression of
neurodegenerative diseases, including Huntington’s (Heng et al.,
2010; Tsvetkov et al., 2010), Alzheimer’s (Ling and Salvaterra,
2009; Wong et al., 2011), and Parkinson’s disease (Yang and
Mao, 2010; Bae et al., 2011 ; Wong et al., 2011; Lynch-Day et al.,
2012). However, whether macroautophagy will play an important
role in methylene blue-mediated neuroprotection is largely
unexplored.
In this study, we evaluated the involvement of macroautophagy
in the methylene blue-mediated neuroprotection. Our aim was
to elucidate the mechanisms by which methylene blue protects
neurons during nutrient insufﬁciency.
MATERIALS AND METHODS
EXPERIMENTAL ANIMALS
C57BL/6 mice (male, 8∼12 week old) were purchased from the
Jackson Laboratory. All animal procedures were approved by the
University of North Texas Health Science Center Animal Care and
Use Committee. All experiments were conducted in compliance
with institutional guidelines and NIH Guidelines for the Use of
Animals in Neuroscience and Behavioral research. Twelve mice
(n = 4 in each group) were intragastrically administrated 50 (low
dose) or 100mg/kg (high dose)methylene blue (American Regent,
Shirley,NY,USA)daily for two consecutiveweeks. Then,micewere
euthanized and brains collected. Cortex, hippocampus and sub-
ventricular zone (SVZ)were isolated, snip frozen in liquidnitrogen
and stored in –80◦C for further analysis.
CELL CULTURE
Mouse HT22 hippocampal cell line was cultured in Dulbecco’s
Modiﬁed Eagle Medium (DMEM) (Gibco) supplemented with
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10% fetal calf serum (Hyclone), 50 IU/ml penicillin and 50 μg/ml
streptomycin (Invitrogen) in a humidiﬁed incubator with 5%CO2
at 37◦C. Cells at passage 8∼12 were adjusted to 1.5 × 105/ml and
were plated in 12-well or 6-well cell culture plates (Corning). At
4 to 6 h after seeding, adherent cells were rinsed with phosphate
buffered saline (PBS) twice and serum-freeDMEM in the presence
or absence of methylene blue was added for indicated time peri-
ods of culture. For methylene blue pretreatment and cell viability
assay, cells were seeded into 96-well plates and cultured for 24 h in
methylene blue-containing DMEM supplemented with 10% fetal
calf serum, then followed by 12-h culture in serum-free DMEM.
Cell viability was determined usingCalcein-AM (Invitrogen) assay
according to the manufacture’s instruction.
FLOW CYTOMETRY
Floating cells and adherent cells were collected by gently ﬂush-
ing the wells with 2 mM EDTA-PBS. Cells were then centrifuged
and stained with propidium iodide (BD Biosciences, cat# 556463)
and Annexin V (BD Biosciences) according to the manufacture’s
instruction.
IMMUNOCHEMICAL STAINING
Cells were seeded in each well of 8-well Lab-TekTM chamber
slides (ThermoScientiﬁc) followedbymethylene blue treatment as
described above. Cells were then ﬁxed with 4% paraformaldehyde
and stained with a rabbit anti-LC3B antibody (Cell signaling) fol-
lowed by stainingwithAlexa Fluor 594-conjugated goat anti rabbit
IgG (Invitrogen). Fluorescent microscopy was conducted using an
Axio Observer Z1 ﬂuorescent microscope (Zeiss).
WESTERN BLOT ANALYSIS
Cell lysate and mouse brain tissue lysate were prepared by homog-
enization in RIPA buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl,
1 mM Na2EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxy-
cholate) and lysis on ice for 30min. Protein amountwas quantiﬁed
using Pierce 660 nm Protein Assay (Thermo Scientiﬁc) following
the manufacture’s instruction. Total protein from each sample was
loaded onto 8% (for acetyl-CoA carboxylase (ACC) and mam-
malian target of rapamycin (mTOR) or 10% (for extracellular
signal-regulated kinase (Erk), Akt, 5′ adenosine monophosphate-
activated protein kinases (AMPKs), B-cell lymphoma 2 (Bcl-2),
and β-actin) SDS-PAGE gel and electrophoresis was performed.
For LC3B, proteins were loaded onto 4–20% Mini-PROTEAN
TGXTM Precast Gels (Bio-Rad). Proteins were then transferred
onto nitrocellulose membranes and blocked with 5% non-fat dry
milk-PBS for 1 h at room temperature (RT). After three washes
with 0.05% Tween-20-PBS, membranes were incubated with the
following primary antibody reagents overnight at 4◦C, respec-
tively: (1) Rabbit monoclonal anti-AMPK, anti-Phospho-AMPK,
anti-ACC and anti-Phospho-ACC (Cell Signaling); (2) Rabbit
monoclonal anti-mTOR and anti-Phospho-mTOR (Cell Signal-
ing); (3) Rabbit monoclonal anti-Erk1/2 (Cell Signaling) and
anti-Phospho-Erk1/2 Thr202/Tyr204 (Cell Signaling); (4) mouse
monoclonal anti-Bcl-2 (Santa Cruz); (5) rabbit polyclonal anti-
Akt (Santa Cruz) and anti-Phospho-Akt1 (Thr 308; Santa Cruz),
and (6)mousemonoclonal anti-β-actin (Santa Cruz). Membranes
were washed three times with PBST and then incubated with
horseradish peroxidase-conjugated secondary antibodies for 1 h
at RT. Membranes were developed with SuperSignal West Pico
Chemiluminescent Substrate (Thermo Scientiﬁc) and were visu-
alized and the optical density of the identiﬁed protein bands on
membraneswas analyzed using a Biospectrum500 imaging system
(UVP, LLC).
STATISTICAL ANALYSIS
Data were analyzed and results were presented asmean± standard
deviation. Student’s t test or one-way ANOVA was used for com-
parison of mean between the groups, and p< 0.05 was considered
signiﬁcant.
RESULTS
METHYLENE BLUE PROTECTS HT22 CELLS FROM SERUM DEPRIVATION
We ﬁrstly tested whether methylene blue exerted cytotoxicity in
cells under normal culture condition. Mouse hippocampal HT22
cells treated with methylene blue ranging from 20 nM to 1 μM
for 24 h did not increase either early or late apoptosis, suggest-
ing that methylene blue has no signiﬁcant pro-apoptotic effect
within this range of concentration (Figures 1A,C). Methylene
blue did not reduce HT22 spontaneous apoptosis, compared with
untreated control group (Figures 1A,C). As predicted, serum
deprivation for 24 h robustly increased both early and late apop-
tosis (Figures 1B,D), which could be signiﬁcantly inhibited by
methylene blue in a dose-dependent manner (Figures 1B,D).
METHYLENE BLUE INDUCES MACROAUTOPHAGY IN HT22 CELLS
To determine whether methylene blue-induced macroautophagy,
HT22 cells were treated with methylene blue at the dose range
between 20 nM and 1 μM and macroautophagy was then detected
with immunocytochemical staining and Western Blot. Serum
deprivation was set as the positive control for macroautophagy.
Anti-LC3B antibody staining displayed a relatively homogenous
distribution of LC3B in HT22 cells, which was predominantly
located in the cytoplasma, consistent with other reports (Steiger-
Barraissoul and Rami, 2009). Notably, perinuclear location of
LC3B was observed after treatment of 20 nM or higher concentra-
tions of methylene blue. In cells treatedwith 1μMmethylene blue,
signiﬁcant increased vesicular structure with strong LC3B staining
in the perinuclear region, a speciﬁc morphological marker of pro-
moted macroautophagy, was visualized, suggesting recruitment
of LC3B into autolysosomes (Figure 2A). Western blot results
showed a dose-and-time-dependent increase of both LC3B-I and
LC3B-II in methylene blue-treated cells, with the most robust
increase being induced by 1 μM methylene blue (Figure 2B).
LC3B type II derives from processed LC3B type I and correlates
well with autophagosome. Moreover, LC3B type II expression was
increased in methylene blue-treated group, compared with serum
deprivation group (Figure 2C). Collectively, these data suggested
methylene blue is an efﬁcient macroautophagy inducer in HT22
cells.
METHYLENE BLUE PROTECTS HT22 CELLS THROUGH
MACROAUTOPHAGY
To test the role of macroautophagy in methylene blue-mediated
neuroprotection, HT22 cells were simultaneously treated with
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FIGURE 1 | Methylene blue attenuates serum deprivation-induced
HT22 cell death. (A,C) Methylene blue itself did not induce HT22
cell apoptosis under normal culture condition. (B,D) Methylene
blue treatment signiﬁcantly attenuated serum deprivation-induced
apoptosis in a dose-dependent manner. *, p < 0.05; ***,
p < 0.001. N, normal culture condition; SD, serum deprivation.
n = 3 in each group, each study has been repeated at least
three times.
methylene blue and serum deprivation for 24 h, and cell apoptosis
were determined by ﬂow cytometry. Consistently, methylene blue
rescued HT22 cells from serum deprivation-induced apoptosis.
However, the recuing effect was signiﬁcantly blocked in the pres-
ence of a potent macroautophagy inhibitor-10 μM chloroquine
(Figure 2D). To conﬁrm that chloroquine inhibited methylene
blue-induced macroautophagy, we tested both LC3B conversion
and p62 level in treated cells. It is well accepted that in cells
undergoing autophagic process, LC3B-II level is increased, while
p62 level is reduced due to its role in targeting proteins into
autolysosome. Themechanismunderlying the inhibitory effects of
chloroquine on macroautophagy is to impairing lysosomal acid-
iﬁcation, thus protein degradation in autolysosome is blocked.
Our data showed methylene blue induced an increased LC3B-II
level as well as a decreased p62 level in HT22 cells in comparison
with the untreated cells, indicatingmethylene blue indeed activates
macroautophagy. In the presence of chloroquine, LC3B-II level
was even higher than that in cells treated with methylene blue
alone, along with a stabilized p62 level, suggesting chloroquine
indeed inhibits protein degradation in autolysosomes (Figure 2E).
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FIGURE 2 | Methylene blue induces macroautophagy in HT22 cells. (A)
Immunocytochemical staining of LC3B showed perinuclear aggregation of
LC3B after 24 h treatment of methylene blue. (B) RepresentativeWestern
blots showed that methylene blue increased both levels of LC3B-I and
LC3B-II in a dose- and time-dependent manner. (C) Compared with 6-h
serum deprivation, methylene blue robustly increased LC3B-II level. (D) Flow
cytometry analysis indicated that chloroquine partially reversed methylene
blue-induced anti-apoptosis after serum deprivation. (E)Western blot showed
chloroquine increased LC3B-II level and stabilized p62 level in methylene
blue-treated cells, suggesting chloroquine inhibited methylene blue-
induced macroautophagy. (F,G) Calcein-AM assay demonstrated that
methylene blue pretreatment signiﬁcantly enhanced cell viability after serum
deprivation which was blocked by chloroquine. *, p < 0.05; **, p < 0.01. N,
normal; U, untreated; SD, serum deprivation; MB, methylene blue; C,
chloroquine. n = 3 in each group, each study has been repeated at least
three time.
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Then, we tested whether methylene blue pre-treatment had
protective effects. Compared with vehicle-treated group, methy-
lene blue-pretreated HT22 cells were more resistant to apoptosis
induced by serum deprivation, which could be blocked by
chloroquine (Figures 2F,G). Chloroquine alone did not result
in HT22 cell apoptosis. Collectively, these data suggested that
macroautophagy play a critical role in methylene blue-mediated
neuroprotection against serum-deprivation.
mTOR SIGNALING WAS NOT INVOLVED IN METHYLENE BLUE-INDUCED
MACROAUTOPHAGY
To determine the signal pathways involved in methylene blue-
induced macroautophagy, HT22 cells were treated with methylene
blue under normal culture condition and Western blots were
performed using anti-Akt and anti-Erk antibodies. As shown in
Figures 3A,B, no signiﬁcant change of activating phosphorylation
of Erk1 or Akt was found in methylene blue-treated cells,
compared with vehicle-treated cells. Although mTOR signaling
has been suggested to be involved in macroautophagy in many
systems, we found that phosphorylation of mTOR was not sig-
niﬁcantly changed upon methylene blue treatment at 100 nM or
1 μM (Figure 3C). Interestingly, the expression level of Bcl-2, a
pro-survival and anti-apoptotic oncogenic protein, was robustly
increased after methylene blue treatment in a dose-dependent
manner (Figure 3D).
ACTIVATION OF AMPK PATHWAY IN METHYLENE BLUE-INDUCES
MACROAUTOPHAGY
5′ Adenosine monophosphate-activated protein kinase pathway
has been characterized as another signal pathway that regulates
macroautophagy (Mihaylova and Shaw, 2011), we determined
whether AMPK pathway was involved in methylene blue-induced
macroautophagy. Compared with control, AMPKα and phos-
phorylated AMPKα were signiﬁcantly increased at 12 and 24 h
FIGURE 3 | Induction of macroautophagy in HT22 cells by methylene
blue is not through mTOR signaling pathway. (A–C) Representative
Western blots showed that methylene blue did not alter activation of
Erk1/2, Akt, or mTOR. (D) RepresentativeWestern bots depict that
Bcl-2 protein level was increased by methylene blue in a dose-dependent
manner.
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FIGURE 4 | Induction of macroautophagy in HT22 cells by methylene
blue is mediated by AMPK pathway. (A) RepresentativeWestern blots
showed that methylene blue increased AMPKα, pAMPKα, AMPKβ1, and
pAMPK β1 in a dose-dependent manner. Activating phosphorylation of ACC
was also enhanced. (B,C) RepresentativeWestern blots demonstrated that
20 μM Compound C (Com C) signiﬁcantly reduced methylene blue-induced
ACC activation and LC3B activation in HT22 cells. Data are representative of
three independent experiments.
FIGURE 5 | Methylene blue induces macroautophagy in mouse
hippocampus throughAMPK signaling pathway. (A) Representative
Western blots depicts that phosphorylation of AMPKα, AMPKβ1 and
ACC were enhanced in methylene blue-treated groups. Conversion of
LC3B-I to LC3B-II was increased in methylene blue-treated groups.
However, mTOR phosphorylation was not altered, compared with
control group. (B) Quantitative analysis showed that methylene blue
increase protein levels of AMPKβ1 and AMPKβ2. *, p < 0.05; ***,
p < 0.001. U, vehicle control; L, low dose methylene blue; H, high dose
methylene blue.
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after methylene blue treatment in a dose-dependent manner.
Similarly, AMPKβ expression was also increased. In addition,
ACC was signiﬁcantly activated at 24 h, conﬁrming activation of
the AMPK pathway (Figure 4A). To test whether AMPK path-
way was critical for methylene blue-induced macroautophagy,
cells were treated with 20 μM compound C, a selective AMPK
inhibitor during the last 4 h of methylene blue treatment.
Compound C co-treatment effectively inhibited methylene blue
induced ACC phosphorylation, indicating that AMPK pathway
was blocked (Figure 4B). Moreover, LC3B type II level was sig-
niﬁcantly alleviated by compound C, suggesting that methylene
blue-induced macroautophagy was indeed via AMPK pathway
(Figure 4C).
METHYLENE BLUE INDUCED MACROAUTOPHAGY IN VIVO
To determine whether methylene blue induces macroautophagy
in vivo, we treated mice with methylene blue for 2 weeks, and
AMPK activation and LC3B type II conversion in the hippocam-
pus and cortex were then examined. As shown in Figures 5
and 6, no signiﬁcant change of AMPKα protein level in the hip-
pocampus and cortex was found upon methylene blue treatment.
However, AMPKα phosphorylation was dramatically enhanced by
methylene blue, especially in high dose-treated group. AMPKβ1
and AMPKβ2 were also signiﬁcantly increased after methylene
blue treatment in a dose-dependent manner. ACC phosphoryla-
tion was promoted in high dose group. Similar to in vitro data,
phosphorylation of mTOR was not signiﬁcantly altered in either
methylene blue-treated group. Compared with vehicle-treated
group, LC3B type II level was dramatically elevated, suggesting
enhanced autophagosome formation in methylene blue-treated
groups. In the SVZ, however, none of these signal pathways
was altered after methylene blue treatment, indicating that the
methylene blue might not affect neural stem/progenitor cells
(Figure 6C). LC3B conversion also showed differences in distinct
brain areas. Methylene blue increased LC3B type II in hip-
pocampi and cortex while slightly decreased LC3B type II in
SVZ of methylene blue-treated mice. Taken together, these data
demonstrated that methylene blue can induce macroautophagy
in hippocampus and cortex through AMPK but not mTOR
pathway in vivo.
DISCUSSION
In this study we ﬁnd that (1) Methylene blue protects HT22 cells
from serum deprivation-induced apoptosis through induction of
macroautophagy; (2)Methylene blue inducesmacroautophagy via
enhancement of AMPK pathway rather than inhibition of mTOR
pathway in vitro; (3) Methylene blue induces macroautophagy via
enhancement of AMPK signal pathway in mouse hippocampus
and cortex in vivo; (4) Methylene blue does not induce macroau-
tophagy in neural stem/progenitor cells located at the mouse SVZ
in vivo.
Neurons in central nervous system are sensitive to inade-
quate serum supply. Studies have demonstrated themorphological
and metabolic characteristics of neurons after serum depriva-
tion (LeBlanc, 1995; Bae et al., 2011; Lesort et al., 1997; Poser
et al., 2003; Chauvier et al., 2005; Steiger-Barraissoul and Rami,
2009). In the current study, we extend our previous ﬁndings and
FIGURE 6 | Methylene blue induces activation of AMPK pathway in
mouse brain. (A,B) RepresentativeWestern blots and quantitative analysis
showed that protein levels of AMPKα, AMPKβ1 and AMPKβ2, but not
mTOR signaling, were increased at cortex in methylene blue-treated
groups. Methylene blue did not signiﬁcantly induce AMPK signaling
activation in SVZ (C) *, p < 0.05; **, p < 0.01. U, vehicle control; L, low
dose methylene blue; H, high dose methylene blue.
demonstrated that methylene blue exerts neuroprotective effect
against serum deprivation. Recentstudies suggest that macroau-
tophagy is neuroprotective against apoptosis induced by serum
deprivation (Steiger-Barraissoul and Rami, 2009). Under nutrient
starvation or energy deprivation circumstances, macroautophagy
is thought to protect cells via saving and recycling materi-
als for maintaining the synthesis of vital macromolecules. Our
data showed that methylene blue treatment effectively protected
starved cells from apoptosis and induced macroautophagy. When
macroautophagy was blocked by chloroquine, the methylene
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blue-mediated neuroprotection was partially inhibited, suggesting
that macroautophagy is involved in the anti-apoptotic action of
methylene blue.
Previous studies have indicated that mTOR-related signal
transduction is the key regulator of macroautophagy (Levine
and Kroemer, 2008; Rabinowitz and White, 2010). Other signal
pathways such as Akt and MAPK/Erk1/2 inﬂuence macroau-
tophagy indirectly through regulating mTOR pathway. A very
recent study has suggested that methylene blue induces macroau-
tophagy to attenuate tauopathy through inhibiting mTOR acti-
vation (Congdon et al., 2012). Our data demonstrated that
methylene blue did not signiﬁcantly activate mTOR signaling
both in vitro and in vivo. Consistently, Akt and Erk signaling,
which has been proven to activate mTOR pathway, were not
inhibited after methylene blue treatment. Bcl-2 was suggested
to inhibit Beclin1-dependent macroautophagy. Methylene blue
robustly increased Bcl-2 protein levels. Therefore, we speculated
that Bcl-2 is not involved in methylene blue-induced macroau-
tophagy. Rather, the anti-apoptotic Bcl-2 might be another mech-
anism contributes to the neuroprotectiove action of methylene
blue.
5′ Adenosine monophosphate-activated protein kinase plays
as a master regulator of cellular energy homeostasis (Hardie
et al., 2012). The kinase is activated in response to stresses that
deplete cellular adenosine triphosphate (ATP) supplies such as
low glucose, hypoxia, ischemia, and heat shock. AMPK activation
positively regulates signal pathways that replenish cellular ATP
supplies while negatively regulates several proteins central to ATP
consuming processes. It has beendemonstrated thatAMPK signal-
ingpositively regulatemacroautophagyby activatingUlk1 through
phosphorylation of Ser317 and Ser777, or indirectly by inhibiting
mTOR signaling (Mihaylova and Shaw, 2011). Our data indicated
that methylene blue induces macroautophagy via, at partially,
AMPK signaling. BothAMPKα andAMPKβ1/2 protein levels were
increased in vitro, whereas the changing pattern was more compli-
cated in vivo, depending on the brain regions. In the hippocampus
and cortex, the action of methylene blue on macroautophagy was
similar to that in vitro, while no effect of methylene blue was
observed in SVZ cells. Since SVZ consists of primitive neural
stem/progenitor cells, we speculated that methylene blue-induced
AMPK activation mainly occurs in mature neurons. Elaborat-
ing studies have shown that methylene blue act as an alternative
electron carrier in the mitochondrial electron transport chain
to enhance ATP production while energy is in short. So it is
unlikely that AMPK activation in methylene blue-treated cells was
due to increased AMP/ATP ratio. Promoted ACC phosphoryla-
tion indicated AMPK pathway was indeed activated. Methylene
blue-induced AMPK activation was accompanied by higher lev-
els of LC3B type II, the activated form of LC3 participating
autophagosome formation. Furthermore, when AMPK inhibitor
was administrated with methylene blue, ACC phosphorylation
was reverted to basal level together with reduced LC3B type
II level.
Taken together, the present study suggests that methylene
blue exert protective effect against serum deprivation, at least
partly, through enhancing macroautophagy. In addition, our
study demonstrated that activation of AMPK pathway, but not
mTOR, is involved in the methylene blue-induced macroauto-
phagy.
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